Quoin Pharma gets Nasdaq bid-price extension to April 28, 2025

Quoin Pharmaceuticals, Ltd.

Nasdaq granted additional 180-day grace period until April 28, 2025 to regain $1.00 minimum bid price compliance.
Company met all other Nasdaq Capital Market initial listing requirements; may effect reverse split if needed.
If compliance not achieved by April 28, 2025, securities will be delisted, subject to appeal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.